Aurobindo Pharma gets USFDA nod for Venlafaxine; stock up

MUMBAI: Aurobindo Pharma has received final approval for its Venlafaxine Extended Release Capsules from the USFDA. These capsules are prescribed for treatment of major depressive disorder and falls under Neurological therapeutic category.

The product has a market size of approximately $2.4 billion for the twelve months ended September 2010.

The stock was at Rs 194.85, up 0.62 per cent on the BSE. It touched a high of Rs 199.50 and low of Rs 193.50 in trade so far.